Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotech companies oppose Trump’s immigration order
The letter, titled US immigration order strikes against biotech, was published in Nature Biotechnology. Some of the big pharma companies on the list include Biogen, Alnylam Pharmaceuticals, Seattle
The letter, titled US immigration order strikes against biotech, was published in Nature Biotechnology. Some of the big pharma companies on the list include Biogen, Alnylam Pharmaceuticals, Seattle
The watchdog filed a complaint in the US District Court for the District of Delaware. It wants the court to prohibit the pharma from submitting repetitive and baseless filings with
The company claims that Parsabiv is the first new therapy approved for the condition in 12 years. It is designed to be administered intravenously three times per week
The company has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA). Ariad’s US marketing application is currently under the US Food and Drug Administration
The phase 2 trial featured 145 adult patients with insomnia disorder where both 5 and 10mg strengths of the hypnotic drug met the primary endpoint while resulting in
The applications are pertained for the use of Keytruda in patients having a type of bladder cancer termed urothelial cancer, in both locally advanced and metastatic stages. One
The two companies confirmed media reports of the proposed offer from Reckitt Benckiser but stated that they were yet to reach a definitive agreement. Reckitt Benckiser, which is
The priority review status will reduce the review clock to six months from the standard 10 months. Even though the action date is not specified, it is expected
After constructive negotiations with several regulators including the US Food and Drug Administration and European Medicines Agency, Summit said it will design a trial intended at assessing the superiority of ridinilazole over the
Xyzal is a single daily dose oral antihistamine, with an active ingredient of levocetirizine dihydrochloride that relieves runny nose, sneezing, itchy watery eyes and itching of the nose